Spinnaker Trust Grows Position in IDEXX Laboratories, Inc. $IDXX

Spinnaker Trust boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 50.3% during the 4th quarter, Holdings Channel reports. The firm owned 6,517 shares of the company’s stock after acquiring an additional 2,182 shares during the quarter. Spinnaker Trust’s holdings in IDEXX Laboratories were worth $4,409,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Old Peak Finance LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $204,000. BNP Paribas purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $180,000. Portland Global Advisors LLC grew its position in IDEXX Laboratories by 323.7% during the 4th quarter. Portland Global Advisors LLC now owns 8,147 shares of the company’s stock worth $5,512,000 after purchasing an additional 6,224 shares during the last quarter. Railway Pension Investments Ltd grew its position in IDEXX Laboratories by 10.0% during the 4th quarter. Railway Pension Investments Ltd now owns 326,080 shares of the company’s stock worth $220,603,000 after purchasing an additional 29,550 shares during the last quarter. Finally, MUFG Securities EMEA plc grew its position in IDEXX Laboratories by 113.8% during the 4th quarter. MUFG Securities EMEA plc now owns 3,274 shares of the company’s stock worth $2,215,000 after purchasing an additional 1,743 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.6%

Shares of IDXX stock opened at $566.79 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market cap of $44.71 billion, a PE ratio of 41.74, a price-to-earnings-growth ratio of 3.27 and a beta of 1.56. The company has a 50-day moving average of $564.32 and a two-hundred day moving average of $635.65. IDEXX Laboratories, Inc. has a 1-year low of $504.56 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on IDXX shares. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.